Scilex Holding Company (SCLX) Stock Score, Valuation & Financial Research
Scilex Holding Company is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for SCLX
Scilex Holding Company currently has a Wall Street Score of 22/100. The stored market price is $5.01. Its financial score is 0/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Scilex Holding Company does
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the tr
SCLX financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $5.01
- Market capitalization:
- $42.5M
- Revenue:
- $33.9M
- Net income:
- $-419.7M
- Free cash flow:
- $3.7M
- Cash:
- $3.4M
- Total debt:
- $106.4M
- EPS:
- -36.48
- Financial score:
- 0/100
- Valuation score:
- 0/100
- Revenue score:
- 17/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $3.7M, showing positive cash generation.
- The balance sheet shows $3.4M of cash versus $106.4M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 0/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SCLX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.